SCHEMBL90794

SCHEMBL90794

CNCC1CCN(C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4328940 1.00
SCHEMBL13325440 1.00
Hydrochloric Acid SCHEMBL31505915 0.98 NCF1 (0.43)
SCHEMBL1488427 0.88 NCF1 (0.52)
SCHEMBL2885366 0.86 CHRM2 (0.38)
SCHEMBL19575592 0.86 CHRM2 (0.38)
SCHEMBL1180350 0.82 L3MBTL1 (0.41)
SCHEMBL10284652 0.82
SCHEMBL19098394 0.81 NCF1 (0.38)
Hydrochloric Acid SCHEMBL4328560 0.80 L3MBTL1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866426-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2024-01-09 US claimed
US-20210171518-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-06-10 US claimed
US-10899755-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2021-01-26 US claimed
US-20200048241-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-02-13 US claimed
WO-2024019995-A1 QUINOXALINEDIONE AND PYRIDO [2, 3-B]PYRAZINE-2, 3-DIONE B CELL LYMPHOMA 6 (BCL6) DEGRADERS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-25 WO disclosed
US-11866426-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2024-01-09 US disclosed
EP-4268808-A1 LIPID NANOPARTICLES COMPRISING MANNOSE OR USES THEREOF EnhancedBio Inc. (KR) 2023-11-01 EP disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
US-20230278987-A1 Antimicrobial Compounds and Methods CURZA GLOBAL, LLC. 2023-09-07 US disclosed
WO-2023089052-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS Samsara Therapeutics Inc. (US) 2023-05-25 WO disclosed
US-20080300403-A1 Method for Production of Quinolone-Containing Lyophilized Preparation DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-12-04 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
US-20080096912-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-04-24 US disclosed
US-20070179184-A1 Novel m3 muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2007-08-02 US disclosed
US-7176313-B2 Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-13 US disclosed
WO-2007007069-A1 AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS VERNALIS (R & D) LIMITED (GB) 2007-01-18 WO disclosed
US-5153203-A QUINOLONE DERIVATIVES AND SALTS THEREOF, PREPARATION PROCESSES THEREOF, AND ANTIBACTERIAL AGENTS CONTAINING THE SAME WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1992-10-06 US disclosed
EP-0390215-A2 Quinolone derivatives and salts thereof, preparation process es thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1990-10-03 EP disclosed